2015
Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder
Scahill L, McCracken JT, King BH, Rockhill C, Shah B, Politte L, Sanders R, Minjarez M, Cowen J, Mullett J, Page C, Ward D, Deng Y, Loo S, Dziura J, McDougle CJ. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder. American Journal Of Psychiatry 2015, 172: 1197-1206. PMID: 26315981, DOI: 10.1176/appi.ajp.2015.15010055.Peer-Reviewed Original ResearchConceptsExtended-release guanfacineModal doseGuanfacine groupWeek 8Common adverse eventsAutism spectrum disorderWeeks of treatmentAttention deficit hyperactivity disorderDeficit hyperactivity disorderPlacebo groupAdverse eventsBlood pressurePlacebo subjectsClinical trialsSpectrum disorderPlaceboGuanfacineHyperactivityPulse rateHyperactivity disorderGroup differencesMotor planningWeeksBrief cognitive batteryDisorders
2009
Comparison of Neurocognitive Functioning in Children Previously Randomly Assigned to Intrathecal Methotrexate Compared With Triple Intrathecal Therapy for the Treatment of Childhood Acute Lymphoblastic Leukemia
Kadan-Lottick NS, Brouwers P, Breiger D, Kaleita T, Dziura J, Northrup V, Chen L, Nicoletti M, Bostrom B, Stork L, Neglia JP. Comparison of Neurocognitive Functioning in Children Previously Randomly Assigned to Intrathecal Methotrexate Compared With Triple Intrathecal Therapy for the Treatment of Childhood Acute Lymphoblastic Leukemia. Journal Of Clinical Oncology 2009, 27: 5986-5992. PMID: 19884541, PMCID: PMC2793042, DOI: 10.1200/jco.2009.23.5408.Peer-Reviewed Original ResearchMeSH KeywordsAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsAttentionChildChild, PreschoolCognitionCross-Sectional StudiesCytarabineFemaleHumansHydrocortisoneInfantInjections, SpinalIntelligence TestsLinear ModelsMaleMemoryMethotrexateNeuropsychological TestsPrecursor Cell Lymphoblastic Leukemia-LymphomaPsychomotor PerformanceTime FactorsTreatment OutcomeUnited StatesConceptsAcute lymphoblastic leukemiaIT therapyIntrathecal methotrexateMethotrexate groupLymphoblastic leukemiaChildhood acute lymphoblastic leukemiaTriple intrathecal therapyPost-therapy periodLong-term neurotoxicityNeurocognitive functioningAssociation of treatmentMajority of childrenCNS prophylaxisFull-scale intelligence quotientIntrathecal therapyNeurologic eventsPsychotropic medicationsVisual-motor integrationTherapy groupAttention/concentrationNeurocognitive evaluationIndex scoreTherapyPatientsMethotrexateA comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia
Kadan-Lottick NS, Brouwers P, Breiger D, Kaleita T, Dziura J, Liu H, Chen L, Nicoletti M, Stork L, Bostrom B, Neglia JP. A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. Blood 2009, 114: 1746-1752. PMID: 19546477, PMCID: PMC2738566, DOI: 10.1182/blood-2008-12-186502.Peer-Reviewed Original ResearchConceptsAcute lymphoblastic leukemiaChildhood acute lymphoblastic leukemiaDexamethasone groupLymphoblastic leukemiaNeurocognitive functioningHigher event-free survival rateEvent-free survival rateCentral nervous system penetrationLong-term cognitive functioningPsychotropic drug usePrevious clinical trialsWorse neurocognitive functioningCorticosteroid RandomizationNeurocognitive toxicityPrednisone groupNeurologic complicationsClinical trialsSignificant overall differenceSurvival rateDrug useYounger ageWorse functioningOlder ageDiagnosisMultisite study